Company Profile
Cullinan Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- CGEM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
17.95 USD (+1.93%)
Close
Last updated: August 6, 2026
943M USD
Market cap
Why the stock is moving
The latest company update was “Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results”. CGEM changed 1.93% and closed at $17.95 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Autoimmune and Oncology Therapeutics
Cullinan Therapeutics develops targeted therapies and immune-cell engagers across autoimmune disease and cancer.
CLN-978
CLN-978 is a compact CD19-directed T-cell engager designed to deplete B cells. It is being studied in systemic lupus erythematosus and rheumatoid arthritis, including multi-dose evaluation.
Zipalertinib
Zipalertinib is an oral EGFR inhibitor under FDA review for previously treated EGFR exon 20 insertion-positive non-small cell lung cancer.
Velinotamig
Velinotamig is a BCMA-directed T-cell engager in clinical development for multiple myeloma.
Future catalysts
Initial CLN-978 data in lupus and rheumatoid arthritis at EULAR 2026.
Multi-dose rheumatoid-arthritis data for CLN-978 in the third quarter of 2026.
Additional clinical data for velinotamig during 2026.
PDUFA target action date for zipalertinib on February 27, 2027.
Recent news
- 01
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Source: Cullinan Therapeutics, Inc.
- 02
- 03
- 04
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Source: Cullinan Therapeutics, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cullinan Therapeutics, Inc. (CGEM)?
Cullinan Therapeutics, Inc. (CGEM) most recently closed at 17.95 USD, a +1.93% move versus the previous session.
What is the market cap of Cullinan Therapeutics, Inc. (CGEM)?
Cullinan Therapeutics, Inc. currently has a market capitalization of 943M USD on BioPharmSignal.
What does Cullinan Therapeutics, Inc. do?
Autoimmune and Oncology Therapeutics Cullinan Therapeutics develops targeted therapies and immune-cell engagers across autoimmune disease and cancer. CLN-978 CLN-978 is a compact CD19-directed T-cell engager designed to deplete B cells. It is being studied in systemic lupus erythematosus and rheumatoid arthritis, including multi-dose...
On which exchange is CGEM stock listed?
Cullinan Therapeutics, Inc. (CGEM) is associated with NASDAQ, United States, Biopharma.
What is CLN-978?
Initial CLN-978 data in lupus and rheumatoid arthritis at EULAR 2026.
Which conditions is Cullinan Therapeutics, Inc. targeting with CLN-978?
Cullinan Therapeutics, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Cullinan Therapeutics, Inc. describe recent progress with CLN-978?
Initial CLN-978 data in lupus and rheumatoid arthritis at EULAR 2026.
What is zipalertinib?
Zipalertinib Zipalertinib is an oral EGFR inhibitor under FDA review for previously treated EGFR exon 20 insertion-positive non-small cell lung cancer.